With lessons learned from Vor, Siddhartha Mukherjee takes a different route to target solid tumors with startup Myeloid
Siddhartha Mukherjee is a busy man these days.
The Pulitzer Prize-winning author, Columbia professor, oncologist, hematologist and leading cancer researcher in 2016 launched Vor, a Cambridge, MA-based startup focused on a new cancer treatment in which cell surface antigens such as CD33 are removed from hematopoietic stem cells. They can then unleash a CAR-T therapy — made from T cells in a patient’s blood and genetically engineered to hunt for the antigens — to treat cancer using the body’s own immune system without attacking healthy cells that would’ve shared those antigens.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
